Gene: GABRA5

2558
-
gamma-aminobutyric acid type A receptor alpha5 subunit
protein-coding
15q12
Ensembl:ENSG00000186297 MIM:137142 Vega:OTTHUMG00000171824 UniprotKB:P31644
NG_032883.1
PubMed
0   ANCO-SNPs
AD
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.156e-1 (AD)  2.916e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg23342980chr15:27111478GABRA5Promoter6.139e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SYN20.923
KCNAB10.918
SVOP0.912
CAMKV0.911
GDA0.906
EFNB30.904
GRIA10.904
TUSC30.902
REEP10.899
CELF40.898

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FLT3LG-0.555
RNF135-0.552
CSAG1-0.546
RUNX3-0.543
IL2RG-0.539
AGTRAP-0.534
MAGEA12-0.528
TGIF1-0.522
A4GALT-0.522
SLC43A3-0.519

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00231TemazepamSmall Molecule846-50-4Approved|InvestigationalTarget
DB00241ButalbitalSmall Molecule77-26-9Approved|IllicitTarget
DB00306TalbutalSmall Molecule115-44-6Approved|IllicitTarget
DB00312PentobarbitalSmall Molecule76-74-4Approved|InvestigationalTarget
DB00371MeprobamateSmall Molecule57-53-4Approved|IllicitTarget
DB00402EszopicloneSmall Molecule138729-47-2Approved|InvestigationalTarget
DB00418SecobarbitalSmall Molecule76-73-3ApprovedTarget
DB00463MetharbitalSmall Molecule50-11-3WithdrawnTarget
DB00546AdinazolamSmall Molecule37115-32-5ApprovedTarget
DB00599ThiopentalSmall Molecule76-75-5ApprovedTarget
DB00683MidazolamSmall Molecule59467-70-8Approved|IllicitTarget
DB00690FlurazepamSmall Molecule17617-23-1Approved|Illicit|InvestigationalTarget
DB00794PrimidoneSmall Molecule125-33-7ApprovedTarget
DB00801HalazepamSmall Molecule23092-17-3Approved|Illicit|WithdrawnTarget
DB00829DiazepamSmall Molecule439-14-5Approved|Illicit|InvestigationalTarget
DB00842OxazepamSmall Molecule604-75-1ApprovedTarget
DB00849MethylphenobarbitalSmall Molecule115-38-8ApprovedTarget
DB00897TriazolamSmall Molecule28911-01-5Approved|InvestigationalTarget
DB00898EthanolSmall Molecule64-17-5ApprovedTarget
DB01198ZopicloneSmall Molecule43200-80-2ApprovedTarget
DB01205FlumazenilSmall Molecule78755-81-4ApprovedTarget
DB01215EstazolamSmall Molecule29975-16-4Approved|IllicitTarget
DB01351AmobarbitalSmall Molecule57-43-2Approved|IllicitTarget
DB01352AprobarbitalSmall Molecule77-02-1Approved|IllicitTarget
DB01353ButethalSmall Molecule77-28-1Approved|IllicitTarget
DB01354HeptabarbitalSmall Molecule509-86-4ApprovedTarget
DB01355HexobarbitalSmall Molecule56-29-1ApprovedTarget
DB01483BarbitalSmall Molecule57-44-3IllicitTarget
DB01496Barbituric acid derivativeSmall MoleculeExperimental|IllicitTarget
DB01544FlunitrazepamSmall Molecule1622-62-4Approved|IllicitTarget
DB01558BromazepamSmall Molecule1812-30-2Approved|Illicit|InvestigationalTarget
DB01559ClotiazepamSmall Molecule33671-46-4Approved|IllicitTarget
DB01567FludiazepamSmall Molecule3900-31-0Approved|IllicitTarget
DB01588PrazepamSmall Molecule2955-38-6Approved|IllicitTarget
DB01589QuazepamSmall Molecule36735-22-5Approved|IllicitTarget
DB01594CinolazepamSmall Molecule75696-02-5ApprovedTarget
DB01595NitrazepamSmall Molecule146-22-5ApprovedTarget
DB05087GanaxoloneSmall Molecule38398-32-2InvestigationalTarget
DB13872LormetazepamSmall Molecule848-75-9ApprovedTarget
DB00186LorazepamSmall Molecule846-49-1ApprovedTarget
DB00189EthchlorvynolSmall Molecule113-18-8Approved|Illicit|WithdrawnTarget
DB00228EnfluraneSmall Molecule13838-16-9Approved|InvestigationalTarget
DB00231TemazepamSmall Molecule846-50-4Approved|InvestigationalTarget
DB00237ButabarbitalSmall Molecule125-40-6Approved|IllicitTarget
DB00241ButalbitalSmall Molecule77-26-9Approved|IllicitTarget
DB00273TopiramateSmall Molecule97240-79-4ApprovedTarget
DB00292EtomidateSmall Molecule33125-97-2ApprovedTarget
DB00306TalbutalSmall Molecule115-44-6Approved|IllicitTarget
DB00312PentobarbitalSmall Molecule76-74-4Approved|InvestigationalTarget
DB00334OlanzapineSmall Molecule132539-06-1Approved|InvestigationalTarget
DB00349ClobazamSmall Molecule22316-47-8Approved|IllicitTarget
DB00371MeprobamateSmall Molecule57-53-4Approved|IllicitTarget
DB00402EszopicloneSmall Molecule138729-47-2Approved|InvestigationalTarget
DB00404AlprazolamSmall Molecule28981-97-7Approved|Illicit|InvestigationalTarget
DB00463MetharbitalSmall Molecule50-11-3WithdrawnTarget
DB00475ChlordiazepoxideSmall Molecule58-25-3Approved|Illicit|InvestigationalTarget
DB00543AmoxapineSmall Molecule14028-44-5ApprovedTarget
DB00555LamotrigineSmall Molecule84057-84-1Approved|InvestigationalTarget
DB00628ClorazepateSmall Molecule23887-31-2Approved|IllicitTarget
DB00659AcamprosateSmall Molecule77337-76-9Approved|InvestigationalTarget
DB00753IsofluraneSmall Molecule26675-46-7ApprovedTarget
DB00794PrimidoneSmall Molecule125-33-7ApprovedTarget
DB00801HalazepamSmall Molecule23092-17-3Approved|Illicit|WithdrawnTarget
DB00818PropofolSmall Molecule2078-54-8Approved|InvestigationalTarget
DB00829DiazepamSmall Molecule439-14-5Approved|Illicit|InvestigationalTarget
DB00842OxazepamSmall Molecule604-75-1ApprovedTarget
DB00897TriazolamSmall Molecule28911-01-5Approved|InvestigationalTarget
DB01028MethoxyfluraneSmall Molecule76-38-0Approved|InvestigationalTarget
DB01049Ergoloid mesylateSmall Molecule8067-24-1ApprovedTarget
DB01068ClonazepamSmall Molecule1622-61-3Approved|IllicitTarget
DB01107MethyprylonSmall Molecule125-64-4Approved|Illicit|WithdrawnTarget
DB01159HalothaneSmall Molecule151-67-7ApprovedTarget
DB01189DesfluraneSmall Molecule57041-67-5ApprovedTarget
DB01205FlumazenilSmall Molecule78755-81-4ApprovedTarget
DB01215EstazolamSmall Molecule29975-16-4Approved|IllicitTarget
DB01236SevofluraneSmall Molecule28523-86-6ApprovedTarget
DB01437GlutethimideSmall Molecule77-21-4Approved|IllicitTarget
DB01588PrazepamSmall Molecule2955-38-6Approved|IllicitTarget
DB01589QuazepamSmall Molecule36735-22-5Approved|IllicitTarget
DB01708PrasteroneSmall Molecule53-43-0Approved|Investigational|NutraceuticalTarget
DB01956TaurineSmall Molecule107-35-7Approved|NutraceuticalTarget
DB09118StiripentolSmall Molecule49763-96-4ApprovedTarget
DB11582ThiocolchicosideSmall Molecule602-41-5Approved|InvestigationalTarget
DB11901ApalutamideSmall Molecule956104-40-8Approved|InvestigationalTarget
DB00555LamotrigineSmall Molecule84057-84-1Approved|InvestigationalTarget
DB06579AdipiplonSmall Molecule840486-93-3InvestigationalTarget
DB139835,7,2G??-trihydroxy-6,8-dimethoxyflavoneSmall Molecule159359-22-5ExperimentalTarget
ID Drug Name Action PubMed
C5822121NMPP1 compound[NTRK2 protein mutant form results in increased susceptibility to 1NMPP1 compound] which results in decreased expression of GABRA5 mRNA27417517
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of GABRA5 mRNA"19114083
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRA5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRA5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRA5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRA5 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of GABRA5 mRNA26690555
D000393Air PollutantsAir Pollutants analog results in increased expression of GABRA5 mRNA21757418
D005680gamma-Aminobutyric AcidGABRA5 protein affects the reaction [gamma-Aminobutyric Acid binds to and results in increased activity of [GABRB2 protein binds to GABRG2 protein]]10987858
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of GABRA5 mRNA24449571
C500175bacoside Abacoside A inhibits the reaction [Pilocarpine results in decreased expression of GABRA5 mRNA]20821261
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of GABRA5 mRNA21839799
D004958EstradiolEstradiol affects the expression of GABRA5 mRNA16000229
D004958Estradiol[Estradiol co-treated with Progesterone] results in increased expression of GABRA5 mRNA19833106
C006780bisphenol Abisphenol A results in decreased expression of GABRA5 mRNA27685785
C006780bisphenol Abisphenol A results in decreased expression of GABRA5 mRNA25181051
D002220CarbamazepineCarbamazepine affects the expression of GABRA5 mRNA25979313
D002220CarbamazepineCarbamazepine inhibits the reaction [Pilocarpine results in decreased expression of GABRA5 mRNA]20821261
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of GABRA5 mRNA12734012
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of GABRA5 mRNA26272509
D019327Copper SulfateCopper Sulfate results in increased expression of GABRA5 mRNA19549813
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of GABRA5 mRNA]27941970
D003975DiazepamDiazepam results in increased activity of GABRA5 protein15613639
D004008DiclofenacDiclofenac results in decreased expression of GABRA5 mRNA26934552
D019422Dietary SucroseDietary Sucrose results in increased expression of GABRA5 mRNA26033743
C118739entinostatentinostat results in increased expression of GABRA5 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRA5 mRNA"27188386
C044610etizolametizolam results in decreased expression of GABRA5 mRNA16107249
D005045EtomidateEtomidate binds to and results in increased activity of GABRA5 protein16597725
D005045EtomidateGABRA5 protein affects the susceptibility to Etomidate16597725
D005557FormaldehydeFormaldehyde results in increased expression of GABRA5 mRNA23649840
D019833Genistein[Genistein co-treated with Methoxychlor] results in increased expression of GABRA5 mRNA21782745
C005499honokiolhonokiol results in increased activity of [GABRA5 protein binds to GABRB2 protein]21699169
C082661imidazenilimidazenil affects the activity of GABRA5 protein15864560
D007649KetamineKetamine results in increased expression of GABRA5 mRNA21712993
D007649KetamineKetamine results in increased expression of GABRA5 protein21712993
C105490L 655,708"L 655,708 binds to and results in decreased activity of GABRA5 protein"20966663
C002385linsidominelinsidomine results in increased oxidation of GABRA5 protein28086193
C042720mercuric bromidemercuric bromide results in decreased expression of GABRA5 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA"27188386
D008727MethotrexateMethotrexate results in decreased expression of GABRA5 mRNA24449571
D008731Methoxychlor[Genistein co-treated with Methoxychlor] results in increased expression of GABRA5 mRNA21782745
D008731MethoxychlorMethoxychlor results in increased expression of GABRA5 mRNA21782745
C028007nickel monoxidenickel monoxide results in decreased expression of GABRA5 mRNA19167457
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of GABRA5 mRNA26272509
D010862Pilocarpinebacoside A inhibits the reaction [Pilocarpine results in decreased expression of GABRA5 mRNA]20821261
D010862PilocarpineCarbamazepine inhibits the reaction [Pilocarpine results in decreased expression of GABRA5 mRNA]20821261
D010862PilocarpinePilocarpine results in decreased expression of GABRA5 mRNA20821261
C006253pirinixic acidpirinixic acid results in increased expression of GABRA5 mRNA12832660
D011374ProgesteroneProgesterone results in decreased expression of GABRA5 mRNA16000229
D011374Progesterone[Estradiol co-treated with Progesterone] results in increased expression of GABRA5 mRNA19833106
D011441PropylthiouracilPropylthiouracil results in increased expression of GABRA5 mRNA24780913
C113975RY 008RY 008 results in increased activity of GABRA5 protein16162846
C571869SH-053-2'F-R-CH3SH-053-2'F-R-CH3 results in increased expression of GABRA5 mRNA27920723
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of GABRA5 mRNA25895662
C017947sodium arsenitesodium arsenite affects the methylation of GABRA5 gene28589171
D012999SomanSoman results in decreased expression of GABRA5 mRNA19281266
D012999SomanSoman binds to and affects the activity of GABRA5 protein22245390
D043343Testosterone PropionateTestosterone Propionate results in increased expression of GABRA5 mRNA16957604
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of GABRA5 mRNA21296121
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of GABRA5 mRNA21570461
D014050TolueneToluene affects the expression of GABRA5 mRNA17108153
C012589trichostatin Atrichostatin A results in increased expression of GABRA5 mRNA24935251
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRA5 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of GABRA5 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased methylation of GABRA5 gene29154799
D014635Valproic AcidValproic Acid results in increased expression of GABRA5 mRNA23179753|2438349
D014635Valproic AcidValproic Acid affects the expression of GABRA5 mRNA17963808
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of GABRA5 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004890GABA-A receptor activityCONTRIBUTES_TOIBA21873635  
GO:0005215transporter activity-TAS1321750  
GO:0005230extracellular ligand-gated ion channel activityCONTRIBUTES_TOIBA21873635  
GO:0005230extracellular ligand-gated ion channel activity-IEA-  
GO:0005237inhibitory extracellular ligand-gated ion channel activity-IBA21873635  
GO:0005254chloride channel activity-IBA21873635  
GO:0005254chloride channel activity-IEA-  
GO:0008503benzodiazepine receptor activityCONTRIBUTES_TOIBA21873635  
GO:0022851GABA-gated chloride ion channel activity-IBA21873635  
GO:0038023signaling receptor activity-TAS1321750  
GO:0050811GABA receptor binding-IEA-  
GO:1904315transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0001662behavioral fear response-IEA-  
GO:0007165signal transduction-IBA21873635  
GO:0007165signal transduction-TAS1321750  
GO:0007214gamma-aminobutyric acid signaling pathway-IBA21873635  
GO:0007214gamma-aminobutyric acid signaling pathway-IEA-  
GO:0007268chemical synaptic transmission-IBA21873635  
GO:0007268chemical synaptic transmission-IEA-  
GO:0007420brain development-IEA-  
GO:0007605sensory perception of sound-IEA-  
GO:0008306associative learning-IEA-  
GO:0034220ion transmembrane transport-IBA21873635  
GO:0042391regulation of membrane potential-IBA21873635  
GO:0043524negative regulation of neuron apoptotic process-IEA-  
GO:0050877nervous system process-IBA21873635  
GO:0051932synaptic transmission, GABAergic-IBA21873635  
GO:0060078regulation of postsynaptic membrane potential-IBA21873635  
GO:0060119inner ear receptor cell development-IEA-  
GO:0060384innervation-IEA-  
GO:0090102cochlea development-IEA-  
GO:1902476chloride transmembrane transport-IBA21873635  
GO:1902476chloride transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005654nucleoplasm-IDA-  
GO:0005829cytosol-IDA-  
GO:0005886plasma membrane-IDA-  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0005887integral component of plasma membrane-TAS1321750  
GO:0030054cell junction-IEA-  
GO:0030425dendrite-IEA-  
GO:0032590dendrite membrane-IBA21873635  
GO:0032809neuronal cell body membrane-IEA-  
GO:0034707chloride channel complex-IEA-  
GO:0043005neuron projection-IBA21873635  
GO:0045202synapse-IBA21873635  
GO:0045211postsynaptic membrane-IEA-  
GO:0098794postsynapse-IBA21873635  
GO:1902711GABA-A receptor complex-IBA21873635  
KEGG ID KEGG Term
hsa04080Neuroactive ligand-receptor interaction
Reactome ID Reactome Term Evidence
R-HSA-112314Neurotransmitter receptors and postsynaptic signal transmissionTAS
R-HSA-112314Neurotransmitter receptors and postsynaptic signal transmissionIEA
R-HSA-112315Transmission across Chemical SynapsesTAS
R-HSA-112315Transmission across Chemical SynapsesIEA
R-HSA-112316Neuronal SystemTAS
R-HSA-112316Neuronal SystemIEA
R-HSA-977441GABA A receptor activationTAS
R-HSA-977443GABA receptor activationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
12555233Association of GABA(A) receptors and alcohol dependence and the effects of genetic imprinting. (2003 Feb)Song JAm J Med Genet B Neuropsychiatr Genet
14745296Association of GABRG3 with alcohol dependence. (2004 Jan)Dick DMAlcohol Clin Exp Res